Navigation Links
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
Date:3/21/2011

VPRIV Important Safety Information

The most serious adverse reactions seen with VPRIV were hypersensitivity reactions. Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, low or high blood pressure, nausea, tiredness and weakness, and fever.  Generally the infusion-related reactions were mild and, in treatment-naïve patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.  

All adult side effects of VPRIV are considered relevant to children (ages 4 to 17 years). Side effects more commonly seen in children compared with adult patients included: upper respiratory tract infection, rash, aPTT prolonged, and fever. The safety of VPRIV has not been established in patients younger than 4 years of age.

As with all therapeutic proteins, there is a potential for immunogenicity. In the clinical studies 1 of 54 treatment-naïve patients treated with VPRIV developed IgG class antibodies.  It is unknown if the presence of IgG antibodies to VPRIV is associated with a higher risk of infusion reactions. 

VPRIV is not available in all countries and prescribing information may differ between countries.  Please consult your local prescribing information.  Full prescribing information for VPRIV in the US can be found at www.VPRIV.com.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
2. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
3. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
4. Reportlinker Adds Shire plc: PharmaVitae Profile
5. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
6. Shire plc - Statement re ProAmatine
7. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
10. Shire plc Appoints Two New Board Directors
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... The College of New Rochelle announced today ... Mid-Hudson Region to be designated as a START-UP NY ... qualified “high-technology” businesses that align with the College’s academic ... been selected for the START-UP NY program and extremely ... economic development in New York by growing business and ...
(Date:8/21/2014)... OTC Markets Group Inc. ... company, on its approval to list on The ... the best marketplace for established U.S. and global ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We ... its growth strategy and achievement of this important ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... 2014 SoundConnect , a ... as one of the nation’s Fastest Growing Private ... the 2nd consecutive year. Inc. magazine today ranked ... 500|5000, an exclusive ranking of the nation's fastest-growing ... look at the most important segment of the ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... Mo., Dec. 8 An investor group in Trinity,Biotech ... developer and manufacturer of,diagnostic products, has reconfigured the slate ... special meeting of the company,s shareholders,that the group is ... behalf of,the group, announced that Robert S. Winter, the ...
... 8 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... will participate in a panel,discussion at the 2008 RBC Capital ... Inflammation and Rheumatology", will take,place on Wednesday, December 10, 2008 ... New York City. , ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and marketer ... received FDA clearance for the,marketing of the ATS 3f(R) Aortic ... improved valve holder accessory device. , ... While the ATS 3f Aortic Bioprosthesis ...
Cached Biology Technology:Investor Group Reconfigures Proposed Slate of Replacement Directors for Trinity Biotech 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3
(Date:8/21/2014)... of scientists including researchers from the University of Georgia recently ... canolain the journal Science . Their discovery paves the ... widely in farming and industry. , Canola is grown ... winter crop is increasingly cultivated in Georgia. Canola oil used ... saturated fat and rich supply of omega-3 fatty acids, but ...
(Date:8/21/2014)... smog-producing toxins in past decade, GTA still violates ... that while the Greater Toronto Area (GTA) has ... to smog, the city continues to violate the ... can cause or aggravate health problems such as ... a set of complex photochemical reactions involving volatile ...
(Date:8/21/2014)... new study of American singles found that during ... highest orgasm rates. On average, men experience orgasm ... orientation making little difference. For women, however, orgasm ... orgasm 62.9 percent of the time during sex ... varies with women,s sexual orientation, with lesbian women ...
Breaking Biology News(10 mins):Canola genome sequence reveals evolutionary 'love triangle' 2Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4
... voracious predators and consume a wide range of prey, which ... proposed for why females eat males before or after mating. ... Ohio found, in a study published in the September issue ... be simpler than previously thought. Males are more likely to ...
... NEW YORK (September 10, 2008)A set of stripy legs in ... something to cheer about, say researchers from the Wildlife Conservation ... apparently has survived in the Democratic Republic of Congo,s Virunga ... increased poaching. "This is the first time this ...
... CORVALLIS, Ore. Contrary to 40 years of conventional wisdom, ... Nature suggests that old growth forests are usually ... from the atmosphere and mitigate climate change for centuries. ... protected by international treaties and have been considered of no ...
Cached Biology News:In spiders, size matters: Small males are more often meals 2Photo reveals rare okapi survived poaching onslaught 2Old growth forests are valuable carbon sinks 2Old growth forests are valuable carbon sinks 3
... ( Abpromise for all tested applications). ... to amino acids 14/26 of Mouse Green cones ... acids 18/30 of tiger red cones opsin 1 ... Entrez Gene ID: 5956 ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
Biology Products: